Review article: colitis-associated cancer -- time for new strategies.

Hdl Handle:
http://hdl.handle.net/10147/208982
Title:
Review article: colitis-associated cancer -- time for new strategies.
Authors:
Shanahan, F
Affiliation:
Department of Medicine, Cork University Hospital and University College Cork,, National University of Ireland, Ireland. fshanahan@ucc.ie
Citation:
Aliment Pharmacol Ther. 2003 Sep;18 Suppl 2:6-9.
Journal:
Alimentary pharmacology & therapeutics
Issue Date:
3-Feb-2012
URI:
http://hdl.handle.net/10147/208982
PubMed ID:
12950414
Abstract:
Colorectal cancer (CRC) remains a feared and potentially life-threatening complication of both ulcerative colitis and Crohn's colitis. Currently, the main preventive strategy is a secondary one, i.e. surveillance colonoscopy usually after 8 years of disease duration, when the risk for neoplasia begins to increase. Despite its widespread acceptance, dysplasia and cancer surveillance is unproven in terms of reducing mortality or morbidity and there is a remarkable lack of uniformity in the manner in which it is practised. In this review article, the pitfalls of dysplasia surveillance are summarized and the need for novel chemopreventive and perhaps pharmabiotic approaches for prevention are highlighted.
Language:
eng
MeSH:
Anticarcinogenic Agents/therapeutic use; Chemoprevention; Colitis, Ulcerative/*complications; Colorectal Neoplasms/etiology/*prevention & control; Crohn Disease/*complications; Humans; Precancerous Conditions; Probiotics/therapeutic use
ISSN:
0269-2813 (Print); 0269-2813 (Linking)

Full metadata record

DC FieldValue Language
dc.contributor.authorShanahan, Fen_GB
dc.date.accessioned2012-02-03T15:09:07Z-
dc.date.available2012-02-03T15:09:07Z-
dc.date.issued2012-02-03T15:09:07Z-
dc.identifier.citationAliment Pharmacol Ther. 2003 Sep;18 Suppl 2:6-9.en_GB
dc.identifier.issn0269-2813 (Print)en_GB
dc.identifier.issn0269-2813 (Linking)en_GB
dc.identifier.pmid12950414en_GB
dc.identifier.urihttp://hdl.handle.net/10147/208982-
dc.description.abstractColorectal cancer (CRC) remains a feared and potentially life-threatening complication of both ulcerative colitis and Crohn's colitis. Currently, the main preventive strategy is a secondary one, i.e. surveillance colonoscopy usually after 8 years of disease duration, when the risk for neoplasia begins to increase. Despite its widespread acceptance, dysplasia and cancer surveillance is unproven in terms of reducing mortality or morbidity and there is a remarkable lack of uniformity in the manner in which it is practised. In this review article, the pitfalls of dysplasia surveillance are summarized and the need for novel chemopreventive and perhaps pharmabiotic approaches for prevention are highlighted.en_GB
dc.language.isoengen_GB
dc.subject.meshAnticarcinogenic Agents/therapeutic useen_GB
dc.subject.meshChemopreventionen_GB
dc.subject.meshColitis, Ulcerative/*complicationsen_GB
dc.subject.meshColorectal Neoplasms/etiology/*prevention & controlen_GB
dc.subject.meshCrohn Disease/*complicationsen_GB
dc.subject.meshHumansen_GB
dc.subject.meshPrecancerous Conditionsen_GB
dc.subject.meshProbiotics/therapeutic useen_GB
dc.titleReview article: colitis-associated cancer -- time for new strategies.en_GB
dc.contributor.departmentDepartment of Medicine, Cork University Hospital and University College Cork,, National University of Ireland, Ireland. fshanahan@ucc.ieen_GB
dc.identifier.journalAlimentary pharmacology & therapeuticsen_GB
dc.description.provinceMunster-
All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.